Position in NVS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$1,089,204
+$153,916 QoQ
Shares Held
6,950
+13.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.58%
of 13F equity value
Holder Rank
#595
of 1,603 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Investment Research Partners LLC holds $11,743,272 across 10 Drug Manufacturers - General names. NVS ranks #5 (9.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
8,904 | $2,261,348 | |
| 2 | LLY |
ELI LILLY & Co
|
1,847 | $2,215,347 | |
| 3 | AMGN |
Amgen Inc
|
3,890 | $1,408,646 | |
| 4 | ABBV |
AbbVie Inc.
|
5,081 | $1,278,582 | |
| 5 | NVS |
Novartis AG
This page
|
6,950 | $1,089,204 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
16,698 | $962,138 | |
| 7 | MRK |
Merck & Co., Inc.
|
6,207 | $797,599 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
5,467 | $690,700 |
All Filings in NVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,089,204 | 6,950 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $935,288 | 6,123 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $854,104 | 6,195 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $784,700 | 6,119 | Shares | Sole | 2025-12-01 | |
| No filing history on record for this holder in this stock. | ||||||